Literature DB >> 6891267

Purification and identification of two structural variants of porcine tissue plasminogen activator by affinity adsorption on fibrin.

P Wallén, N Bergsdorf, M Rånby.   

Abstract

Porcine tissue plasminogen activator has been purified from delipidized heart tissue by affinity adsorption to fibrin. A crude fraction is prepared from an acid tissue extract by precipitation with ammonium sulphate. The tissue activator of this fraction is isolated by adsorption on fibrin and elution with KSCN. The procedure also includes chromatography on arginine-Sepharose and two gel-filtration steps. The final product has a specific activity of 250 000 IU/mg (+/- 16 000) as compared to an international urokinase reference preparation. The yield calculated from the active ammonium sulphate precipitate is about 28%. An approx. 7 000-fold increase of specific activity is obtained, most of which is achieved in the fibrin step. The native tissue plasminogen activator consists of a single chain molecule with a molecular weight of 64 000 as measured by SDS-polyacrylamide gel electrophoresis. In a previous report, it was claimed that the activator is composed of two disulphide-connected polypeptide chains. These results were due to a preparation artefact, caused by proteolytic activity present in the tissue extracts. The introduction of the protease inhibitor aprotinin and 6-amino-hexanoic acid in the purification procedure has abolished the effect of the protease contaminant, leading to the production of a one-chain activator. Treatment with plasmin transforms the native, one-chain tissue activator into a variant composed of two chains of about equal size (Mr 32 000) connected by disulphide bonding. This modified activator is indistinguishable from the one obtained at insufficient protection against proteolytic enzymes. The cleavage by plasmin causes about an 8-fold increase of amidolytic activity as measured on H-D-Val-Gly-Arg-p-nitroanilide. The fibrinolytic activity as measured by clot lysis in only slightly increased. The physiological significance of the cleavage is discussed.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6891267     DOI: 10.1016/0304-4165(82)90105-2

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  12 in total

1.  Localization of the binding site of tissue-type plasminogen activator to fibrin.

Authors:  A Ichinose; K Takio; K Fujikawa
Journal:  J Clin Invest       Date:  1986-07       Impact factor: 14.808

2.  The genetic relationships between the kringle domains of human plasminogen, prothrombin, tissue plasminogen activator, urokinase, and coagulation factor XII.

Authors:  F J Castellino; J M Beals
Journal:  J Mol Evol       Date:  1987       Impact factor: 2.395

3.  Tissue plasminogen activator-based nanothrombolysis for ischemic stroke.

Authors:  Shan Liu; Xiaozhou Feng; Rong Jin; Guohong Li
Journal:  Expert Opin Drug Deliv       Date:  2017-09-28       Impact factor: 6.648

Review 4.  Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.

Authors:  D Collen; H R Lijnen; P A Todd; K L Goa
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

5.  Glycosylation and secretion of human tissue plasminogen activator in recombinant baculovirus-infected insect cells.

Authors:  D L Jarvis; M D Summers
Journal:  Mol Cell Biol       Date:  1989-01       Impact factor: 4.272

6.  A novel protease obtained from FBS-containing culture supernatant, that processes single chain form hepatocyte growth factor to two chain form in serum-free culture.

Authors:  T Shimomura; M Ochiai; J Kondo; Y Morimoto
Journal:  Cytotechnology       Date:  1992       Impact factor: 2.058

7.  Plasmin-mediated fibrinolysis by variant recombinant tissue plasminogen activators.

Authors:  S Urano; A R Metzger; F J Castellino
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

8.  Interaction of mutants of tissue-type plasminogen activator with liver cells: effect of domain deletions.

Authors:  J Kuiper; A Van't Hof; M Otter; E A Biessen; D C Rijken; T J van Berkel
Journal:  Biochem J       Date:  1996-02-01       Impact factor: 3.857

9.  Variants of human tissue-type plasminogen activator that lack specific structural domains of the heavy chain.

Authors:  M J Gething; B Adler; J A Boose; R D Gerard; E L Madison; D McGookey; R S Meidell; L M Roman; J Sambrook
Journal:  EMBO J       Date:  1988-09       Impact factor: 11.598

10.  Inactive proenzyme to tissue-type plasminogen activator from human melanoma cells, identified after affinity purification with a monoclonal antibody.

Authors:  P A Andreasen; L S Nielsen; J Grøndahl-Hansen; L Skriver; J Zeuthen; R W Stephens; K Danø
Journal:  EMBO J       Date:  1984-01       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.